Kardigan raised $400 million in an IPO aimed at supporting three clinical-stage cardiovascular drugs. The offering contributes to a buoyant IPO environment for biotech in 2026, with the company joining a small set of large listings exceeding $400 million in proceeds. The fundraising is intended to advance the company’s clinical-stage pipeline through upcoming development milestones. The deal also signals that investors continue to favor cardio-focused development programs when early clinical evidence supports differentiated mechanisms or endpoints. As a newly listed public company, Kardigan will face scrutiny on trial timelines and readout clarity for each candidate, particularly in a market where large-cap investors demand catalysts within 12–24 months. For the sector, the IPO adds liquidity and may increase competitive activity in cardiometabolic innovation, including trial capacity and partnering interest.